Katrien Verschueren

Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis

James F. Howard, Vera Bril, Ted M. Burns et al. · Neurology · 2019 · 268 citations · Full text

Antithrombotic drug candidate ALX-0081 shows superior preclinical efficacy and safety compared with currently marketed antiplatelet drugs

Hans Ulrichts, Karen Silence, Anne Schoolmeester et al. · Blood · 2011 · 178 citations · Full text

Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia

Adrian C. Newland, Blanca Sánchez‐González, László Rejtő et al. · American Journal of Hematology · 2019 · 173 citations · Full text

RCT to evaluate the influence of adjuvant medical treatment of peritoneal endometriosis on the outcome of IVF

W. Decleer, Kaan Osmanagaoglu, Katrien Verschueren et al. · Human Reproduction · 2016 · 49 citations · Full text

OP0043 Twenty-Four Weeks of Treatment with a Novel Anti-IL-6 Receptor Nanobody® (ALX-0061) Resulted in 84% ACR20 Improvement and 58% DAS28 Remission in a Phase I/Ii Study in RA

Josefin-Beate Holz, L. Sargentini-Maier, Steven De Bruyn et al. · Annals of the Rheumatic Diseases · 2013 · 22 citations